Abstract
Abstract
Background
Despite the increasing incidence of aplastic anemia in China, few studies have explored its effect on the patients’ quality of life from the perspective of these patients. In fact, patients with aplastic disorder live with the disease for a long time, and need to face a variety of difficult realities, including multiple disease symptoms and drug side effects, heavy burden of medical costs, difficulties in social reintegration, and negative emotional distress. Therefore, this study used descriptive qualitative research to explore the direct and rich quality-of-life experiences of patients with aplastic anemia.
Methods
A total of 19 patients with aplastic anemia were recruited in this study using purposive sampling combined with maximum variation strategy. 5 of the patients with AA were from northern China, and the others were from southern China. Data were collected using semi-structured interviews and analyzed using the conventional content analysis method.
Results
This study yielded important information about the experiences of patients with aplastic anemia in China. The content analysis method finally identified 3 themes and 9 sub-themes, including: physical symptoms (declining physical capacity, treatment-related symptoms, changes in body image), psychological symptoms (mood changes related to the stage of the disease, change in self-image, growth resulting from the disease experience), social burden (decline in career development, perceived burden to the family, social stigma). Patients with AA from different regions didn’t show much difference in quality of life.
Conclusions
Aplastic anemia affects the physical, psychological, and social aspects of patients’ lives. Therefore, health care providers need to consider the patients’ physical response and psychological feelings to provide relevant medical guidance and multi-channel social support that would improve their confidence and quality of life.
Clinical trial registration
Name: Development and preliminary application of Quality of Life Scale for Patients with Aplastic Anemia. Number: ChiCTR2100047575. URL: http://www.chictr.org.cn/login.aspx?referurl=%2flistbycreater.aspx.
Funder
Medical and Health Science and Technology Program of Zhejiang Province Health Department
Traditional Chinese Medicine Science and Technology Project of Zhejiang Province
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics (clinical),General Medicine
Reference44 articles.
1. Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, et al. British society for standards in haematology. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207.
2. Wang L, Liu H. Pathogenesis of aplastic anemia. Hematology. 2019;24(1):559–66.
3. Kojima S. Why is the incidence of aplastic anemia higher in Asia? Expert Rev Hematol. 2017;10(4):277–9.
4. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017). Chin J Hematol. 2017;38(1):1–5.
5. Li SS, Hsu YT, Chang C, Lee SC, Yen CC, Cheng CN, Chen JS, Lin SH, Chang KC, Chen TY. Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019;98(1):29–39.